Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis

E. Carrillo, S. Ahmed, K. Goldsmith-Pestana, J. Nieto, Y. Osorio, Bruno Travi, J. Moreno, D. McMahon-Pratt

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The P-8 proteoglycolipid complex (P-8 PGLC), an amastigote antigen of Leishmania pifanoi, has been demonstrated to induce protection in mouse models, as well as to induce Tc1/Th1-like cellular responses in American cutaneous leishmaniasis patients. Because the immunization with P-8 PGLC in the murine model does not appear to be genetically restricted, we have studied the reactivity of the P-8 PGLC in Leishmania infantum infected dogs. In this study, it is shown that PBMC from experimentally infected dogs (asymptomatic, oligosymptomatic) significantly proliferated in response to soluble leishmanial antigen (SLA) or the P-8 PGLC. Further, quantification of the gene expression induced by the stimulation with P-8 in asymptomatically infected dogs showed an up-regulation of IFN-γ and TNF-α, which were three to 4-fold higher than that induced by soluble Leishmania antigen (SLA). While no measurable induction of IL-10 was observed, low levels of IL-4 mRNA were observed in response to both P-8 and SLA antigens. Thus, our studies establish that P-8 is recognized by infected canines and elicits a potentially curative/protective Th1-like immune response. The identification of Leishmania antigens that elicit appropriate immune responses across different host species (humans, canine) and disease manifestations (cutaneous or visceral) could be an advantage in generating a general vaccine for leishmaniasis.

Original languageEnglish (US)
Pages (from-to)1534-1543
Number of pages10
JournalVaccine
Volume25
Issue number8
DOIs
StatePublished - Feb 9 2007
Externally publishedYes

Fingerprint

amastigotes
visceral leishmaniasis
Visceral Leishmaniasis
Canidae
Theoretical Models
immune response
antigens
Antigens
dogs
Leishmania
Cutaneous Leishmaniasis
Dogs
Leishmaniasis Vaccines
animal models
Leishmania infantum
Dog Diseases
cutaneous leishmaniasis
leishmaniasis
interleukin-4
interleukin-10

Keywords

  • Canine
  • Cytokine
  • Immunogenicity
  • Leishmania
  • P-8

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Carrillo, E., Ahmed, S., Goldsmith-Pestana, K., Nieto, J., Osorio, Y., Travi, B., ... McMahon-Pratt, D. (2007). Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine, 25(8), 1534-1543. https://doi.org/10.1016/j.vaccine.2006.10.036

Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. / Carrillo, E.; Ahmed, S.; Goldsmith-Pestana, K.; Nieto, J.; Osorio, Y.; Travi, Bruno; Moreno, J.; McMahon-Pratt, D.

In: Vaccine, Vol. 25, No. 8, 09.02.2007, p. 1534-1543.

Research output: Contribution to journalArticle

Carrillo, E, Ahmed, S, Goldsmith-Pestana, K, Nieto, J, Osorio, Y, Travi, B, Moreno, J & McMahon-Pratt, D 2007, 'Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis', Vaccine, vol. 25, no. 8, pp. 1534-1543. https://doi.org/10.1016/j.vaccine.2006.10.036
Carrillo, E. ; Ahmed, S. ; Goldsmith-Pestana, K. ; Nieto, J. ; Osorio, Y. ; Travi, Bruno ; Moreno, J. ; McMahon-Pratt, D. / Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. In: Vaccine. 2007 ; Vol. 25, No. 8. pp. 1534-1543.
@article{52b70c17834c498f83a497f5a3af275a,
title = "Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis",
abstract = "The P-8 proteoglycolipid complex (P-8 PGLC), an amastigote antigen of Leishmania pifanoi, has been demonstrated to induce protection in mouse models, as well as to induce Tc1/Th1-like cellular responses in American cutaneous leishmaniasis patients. Because the immunization with P-8 PGLC in the murine model does not appear to be genetically restricted, we have studied the reactivity of the P-8 PGLC in Leishmania infantum infected dogs. In this study, it is shown that PBMC from experimentally infected dogs (asymptomatic, oligosymptomatic) significantly proliferated in response to soluble leishmanial antigen (SLA) or the P-8 PGLC. Further, quantification of the gene expression induced by the stimulation with P-8 in asymptomatically infected dogs showed an up-regulation of IFN-γ and TNF-α, which were three to 4-fold higher than that induced by soluble Leishmania antigen (SLA). While no measurable induction of IL-10 was observed, low levels of IL-4 mRNA were observed in response to both P-8 and SLA antigens. Thus, our studies establish that P-8 is recognized by infected canines and elicits a potentially curative/protective Th1-like immune response. The identification of Leishmania antigens that elicit appropriate immune responses across different host species (humans, canine) and disease manifestations (cutaneous or visceral) could be an advantage in generating a general vaccine for leishmaniasis.",
keywords = "Canine, Cytokine, Immunogenicity, Leishmania, P-8",
author = "E. Carrillo and S. Ahmed and K. Goldsmith-Pestana and J. Nieto and Y. Osorio and Bruno Travi and J. Moreno and D. McMahon-Pratt",
year = "2007",
month = "2",
day = "9",
doi = "10.1016/j.vaccine.2006.10.036",
language = "English (US)",
volume = "25",
pages = "1534--1543",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis

AU - Carrillo, E.

AU - Ahmed, S.

AU - Goldsmith-Pestana, K.

AU - Nieto, J.

AU - Osorio, Y.

AU - Travi, Bruno

AU - Moreno, J.

AU - McMahon-Pratt, D.

PY - 2007/2/9

Y1 - 2007/2/9

N2 - The P-8 proteoglycolipid complex (P-8 PGLC), an amastigote antigen of Leishmania pifanoi, has been demonstrated to induce protection in mouse models, as well as to induce Tc1/Th1-like cellular responses in American cutaneous leishmaniasis patients. Because the immunization with P-8 PGLC in the murine model does not appear to be genetically restricted, we have studied the reactivity of the P-8 PGLC in Leishmania infantum infected dogs. In this study, it is shown that PBMC from experimentally infected dogs (asymptomatic, oligosymptomatic) significantly proliferated in response to soluble leishmanial antigen (SLA) or the P-8 PGLC. Further, quantification of the gene expression induced by the stimulation with P-8 in asymptomatically infected dogs showed an up-regulation of IFN-γ and TNF-α, which were three to 4-fold higher than that induced by soluble Leishmania antigen (SLA). While no measurable induction of IL-10 was observed, low levels of IL-4 mRNA were observed in response to both P-8 and SLA antigens. Thus, our studies establish that P-8 is recognized by infected canines and elicits a potentially curative/protective Th1-like immune response. The identification of Leishmania antigens that elicit appropriate immune responses across different host species (humans, canine) and disease manifestations (cutaneous or visceral) could be an advantage in generating a general vaccine for leishmaniasis.

AB - The P-8 proteoglycolipid complex (P-8 PGLC), an amastigote antigen of Leishmania pifanoi, has been demonstrated to induce protection in mouse models, as well as to induce Tc1/Th1-like cellular responses in American cutaneous leishmaniasis patients. Because the immunization with P-8 PGLC in the murine model does not appear to be genetically restricted, we have studied the reactivity of the P-8 PGLC in Leishmania infantum infected dogs. In this study, it is shown that PBMC from experimentally infected dogs (asymptomatic, oligosymptomatic) significantly proliferated in response to soluble leishmanial antigen (SLA) or the P-8 PGLC. Further, quantification of the gene expression induced by the stimulation with P-8 in asymptomatically infected dogs showed an up-regulation of IFN-γ and TNF-α, which were three to 4-fold higher than that induced by soluble Leishmania antigen (SLA). While no measurable induction of IL-10 was observed, low levels of IL-4 mRNA were observed in response to both P-8 and SLA antigens. Thus, our studies establish that P-8 is recognized by infected canines and elicits a potentially curative/protective Th1-like immune response. The identification of Leishmania antigens that elicit appropriate immune responses across different host species (humans, canine) and disease manifestations (cutaneous or visceral) could be an advantage in generating a general vaccine for leishmaniasis.

KW - Canine

KW - Cytokine

KW - Immunogenicity

KW - Leishmania

KW - P-8

UR - http://www.scopus.com/inward/record.url?scp=33846115054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846115054&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.10.036

DO - 10.1016/j.vaccine.2006.10.036

M3 - Article

C2 - 17178178

AN - SCOPUS:33846115054

VL - 25

SP - 1534

EP - 1543

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 8

ER -